G1 Therapeutics (NASDAQ:GTHX) reported preliminary overall survival results from a Phase 2 trial of trilaciclib in women with metastatic triple-negative breast cancer (mTNBC).
Trilaciclib is a myelopreservation agent designed to protect the bone marrow from damage by chemotherapy.
In the Phase 2 trial, women with mTNBC lived significantly longer when receiving trilaciclib and chemotherapy, compared with those receiving chemotherapy alone.
“TNBC is the most aggressive type of breast cancer, and women diagnosed with metastatic TNBC need new treatment options,” Dr. Mark Velleca, G1’s CEO, said in a statement.
“We look forward to sharing these data with regulators, as well as presenting findings from this trial at a medical meeting later this year,” he added.
G1 plans to initiate additional trials to evaluate the myelopreservation and survival benefits of trilaciclib in other tumor types and chemotherapy regimens. The company expects to submit marketing applications in the U.S. and Europe for myelopreservation in small cell lung cancer in 2020.
